Printer Friendly

LIDAK PHARMACEUTICALS RECEIVES FEDERAL GRANT FOR STUDIES OF POTENTIAL CANCER THERAPY

 LIDAK PHARMACEUTICALS RECEIVES FEDERAL GRANT
 FOR STUDIES OF POTENTIAL CANCER THERAPY
 LA JOLLA, Calif., Sept. 24 /PRNewswire/ -- LIDAK Pharmaceuticals (NASDAQ: LDAKA) today announced it has been awarded a Phase II grant from the National Institutes of Health's Small Business Innovation Research (SBIR) program. The $428,000 award is for further development of its Large Multivalent Immunogen (LMI) technology for potential use in the treatment of cancer in humans.
 The primary goals of the two-year grant are to further define the mechanisms by which LMI treatment reduces tumor growth and to complete the pre-clinical development necessary for the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration. LIDAK anticipates that clinical trials will be conducted initially on the effectiveness of LMI in the treatment of melanoma.
 "We are placing a high priority on the development of LMI for the treatment of various cancers and are eager to complete preparations for the submission of an IND," said David H. Katz, president and chief executive officer. "We consider this award to be an endorsement of both the scientific progress we have made and the potential commercial value of LMI technology."
 In Phase I SBIR studies, LIDAK's LMI technology was shown to be effective in the treatment of tumors in mice. As reported in the July 1, 1992 issue of the Journal of Immunology, this anti-tumor effect results from stimulating and activating cytotoxic T lymphocytes (CTL), or "killer cells" of the human immune system, to attack and kill cancer cells. LMI significantly strengthens CTL protective response by attaching isolated foreign cancer antigens onto a solid support artificial membrane.
 LIDAK Pharmaceuticals is attempting to develop pharmaceutical products for the health care industry. In addition to the development of its LMI technology, the company is focusing its efforts on the commercialization of LIDAKOL as a treatment for herpes and other indications. The company is also developing Free Fatty Acid technology as a possible clinical diagnostic assay for the prediction and monitoring of cancer and diabetes. Finally, it is utilizing surrogate human immune system reconstituted mice for evaluating new potential anti-AIDS drugs and new diagnostic and treatment approaches to cancer.
 -0- 9/24/92
 /CONTACT: David H. Katz, president and CEO of LIDAK Pharmaceuticals, 619-450-1538/
 (LDAKA) CO: LIDAK Pharmaceuticals ST: California IN: MTC SU:


KJ -- LA005 -- 2944 09/24/92 09:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 24, 1992
Words:393
Previous Article:TSS LTD. REPORTS START UP OF TWO COUPON PROGRAMS; INCREASED REVENUES AND OPERATING COSTS SAVINGS
Next Article:PROCTER & GAMBLE WILL PRODUCE UP TO 15 MILLION GALLONS OF BIODIESEL FOR INTERCHEM
Topics:


Related Articles
LIDAK PHARMACEUTICALS REPORTS RESULTS
LIDAK PHARMACEUTICALS REPORTS RESULTS
LIDAK PHARMACEUTICALS ANNOUNCES RESULTS
LIDAK PHARMACEUTICALS REPORTS YEAR-END FINANCIAL RESULTS
LIDAK PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS
LIDAK PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS
LIDAK PHARMACEUTICALS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS
LIDAK PHARMACEUTICALS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
LIDAK PHARMACEUTICALS REPORTS YEAR-END FINANCIAL RESULTS AND CLINICAL TRIAL UPDATE
LIDAK PHARMACEUTICALS REPORTS FISCAL 1995 YEAR-END RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters